
欧洲白细胞去除术市场预测至 2028 年 - COVID-19 影响和按产品类型(白细胞去除术设备和白细胞去除术一次性用品)、应用(研究应用和治疗应用)和最终用户(血液成分提供商和血液中心、学术和研究机构、制药和生物技术公司、医院和输血中心)
No. of Pages: 132 | Report Code: TIPRE00025790 | Category: Life Sciences
No. of Pages: 132 | Report Code: TIPRE00025790 | Category: Life Sciences
欧洲白细胞分离术市场基于三个大国进行分析:德国、英国、法国、意大利、西班牙和鱼子。德国在白细胞分离术市场的增长中贡献了主要份额。德国因其稳定的增长和创新的医疗保健方法而成为一个有吸引力的市场。据联邦统计局统计,2019年德国卫生支出达4600.3亿美元。德国医疗器械市场是欧洲最大的医疗器械市场之一,也是世界第三大医疗器械市场。全球对高度创新技术以及诊断、治疗和微创设备的需求仍然很高。德国的医疗器械制造商还可以为各种研究项目申请国家资助,并获得重建贷款公司(KfW)的资助。制造商越来越关注新产品开发和战略合作以开发白细胞分离术等先进诊断设备,预计将推动市场增长。德国拥有强大的卫生系统,特别是基础设施、病床和训练有素的工作人员。据卫生部称,2018年,1,925家医院、1,142家康复中心和19,075家药房拥有近498,400张床位。发达的基础设施使拥有560万员工的健康产业成为德国最大的雇主。 2016 年,德国约有 13,900 人患上白血病,其中 4% 年龄在 15 岁以下。在进入青年期的过程中,这种风险会降低,但从 30 岁开始又会再次增加。男性的发病率高于女性。每 67 名男性和每 87 名女性中就有 1 人会在一生中的某个阶段患上白血病。
由于该地区 COVID-19 病例呈指数级增长,欧洲经济受到严重影响。俄罗斯、西班牙、意大利、德国、法国和英国是受影响最严重的欧洲国家。欧洲各国在今年年初成功缓解疫情后,Covid-19 病例再次出现。许多国家现在每天宣布的病例数量比今年早些时候第一波疫情期间还要多。根据欧洲疾病预防和控制中心 (ECDC) 的数据,英国、西班牙、意大利和爱尔兰正在重新实施封锁。由于第二波 COVID-19 病例,许多国家的政府正在努力扩大检测能力,这正在推动市场的增长。
欧洲白细胞分离术市场预计将从2021年的2255万美元增长到2028年的3926万美元;预计 2021 年至 2028 年复合年增长率为 8.2%。治疗性单采术是指一种体外治疗,涉及选择性去除血液循环中的细胞或其他有针对性的异常物质。最近,该技术已被探索用于治疗各种医疗状况。体外光采术(ECP)是一种用于治疗淋巴瘤的方法。在此过程中,从血液中收集白细胞(WBC),用光激活药物进行处理,并暴露在紫外线下,然后将其输回患者体内。治疗性血浆置换是治疗多发性硬化症、骨髓瘤和白血病等疾病的潜在方法。该技术从患者的血液中抽取血浆,并用新鲜的供体血浆或瓶装人白蛋白溶液代替。此外,双重过滤血浆置换技术用于快速进展性肾小球肾炎,低密度脂蛋白(LDL)血浆置换术或白细胞置换术用于肾病综合征。这些技术是用于治疗肾脏疾病的两种主要的单采疗法。因此,单采技术在治疗领域的广泛应用正在成为白细胞分离市场的普遍趋势。
Strategic insights for Europe Leukapheresis involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 22.55 Million |
Market Size by 2028 | US$ 39.26 Million |
Global CAGR (2021 - 2028) | 8.2% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By 产品类型
|
Regions and Countries Covered | 欧洲
|
Market leaders and key company profiles |
The regional scope of Europe Leukapheresis refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Leukapheresis Market is valued at US$ 22.55 Million in 2021, it is projected to reach US$ 39.26 Million by 2028.
As per our report Europe Leukapheresis Market, the market size is valued at US$ 22.55 Million in 2021, projecting it to reach US$ 39.26 Million by 2028. This translates to a CAGR of approximately 8.2% during the forecast period.
The Europe Leukapheresis Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Leukapheresis Market report:
The Europe Leukapheresis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Leukapheresis Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Leukapheresis Market value chain can benefit from the information contained in a comprehensive market report.